Bicara Therapeutics director Jeremy Bender discloses holdings

Bicara Therapeutics Inc. reports that Jeremy Bender is a director of the company and has submitted an initial statement of beneficial ownership.

Accepted by SEC EDGAR 07/29/2026 - 04:17 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reports that Jeremy Bender is a director of the company and has submitted an initial statement of beneficial ownership. The report lists no transactions or specific equity holdings for him, and references an accompanying Exhibit 24 - Power of Attorney.

Key Figures

Reported transactions: 0 Holding entries: 0

2 metrics

Reported transactions 0 Total buy, sell, acquire, dispose and other transactions for Jeremy Bender

Holding entries 0 Number of equity or derivative positions reported for Jeremy Bender

Key Terms

Exhibit 24, Power of Attorney

2 terms

Exhibit 24 regulatory

"remarks: "Exhibit 24 - Power of Attorney""

Power of Attorney regulatory

"remarks: "Exhibit 24 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BCAX Form 3 for Jeremy Bender disclose?

The Form 3 for BCAX identifies Jeremy Bender as a director and serves as his initial statement of beneficial ownership. It reports no transactions, no specific share or option holdings, and references an attached Exhibit 24 - Power of Attorney.

Does Jeremy Bender report owning any Bicara Therapeutics (BCAX) shares?

No specific BCAX shareholdings are reported for Jeremy Bender in this Form 3. The structured data show zero transactions and zero holding entries, indicating no reportable equity or derivative positions as of the reporting date.

What is Jeremy Bender’s role at Bicara Therapeutics Inc. (BCAX)?

Jeremy Bender is listed as a director of Bicara Therapeutics Inc. in the Form 3. He is not reported as an officer and is not identified as a ten percent owner, based on the role flags in the ownership report.

Are any derivative securities reported for Jeremy Bender in the BCAX Form 3?

No. The Form 3 derivative summary for BCAX shows no derivative positions reported for Jeremy Bender. Derivative transaction counts and holding entries are zero, indicating no options, warrants, or similar instruments disclosed in this report.

What additional documents are referenced in Jeremy Bender’s BCAX ownership report?

The report’s remarks reference “Exhibit 24 - Power of Attorney”. This indicates a separate Power of Attorney document authorizing certain actions related to SEC reporting, associated with director Jeremy Bender’s beneficial ownership disclosure for BCAX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bender Jeremy

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/28/2026

3. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ryan Cohlhepp, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)